Treatment of diabetic neuropathy with Milgamma N

 

Abstract:

 

50 patients with diabetic neuropathy – 27 females and 23 males, of mean age 41.3 ± 9.2 years and mean duration of diabetes 11.7 ± 5.2 years were treated with Milgamma N (Worwag Pharma) for 21 days, two capsules q. i. d., thereafter one capsule t. i. d. for 69 days. Signs and symptoms of diabetic neuropathy, neurological examination, vibration perception threshold and in some patients tests for autonomic neuropathy and EMC were evaluated before treatment as well as on the 21st day and by the end of the third month. Patients' complaints of tingling, pins and needles, numbness of the feet decreased by the end of the 1st week and nearly disappeared after the 1st month. Pain was estimated according to a 20 degree scale. Patients reported a reduction of pain by the end of the 2nd week, and on the 3rd week we found a decrease of 35 % (from 12 before treatment to 7.8), and by the end of the 3rd month it fell by 67 % (down to 4). Some patients reported that crams during the night had disappeared. We found a significant improvement in one patient with severe diabetic enteropathy, where the defecations were normalised after the 1st month of treatment. Some parameters of autonomic neuropathy in some of the patients also improved. Vibration perception threshold was measured by means of tuning the fork of Rydel-Seiffer (0 – 8). It was reduced in all patients before treatment – at the great toe – from 0 to 4.0 (mean 2.5 ± 0.6), at the first metatarsal – from 0 to 4.5 (mean 2.9 ± 1.1) and at the medial malleolus from 0 to 5.0 (mean 3.4 ± 1.3). Vibration perception threshold increased on the 21 st day of treatment by 0.5 – 0.7, and by the end of the third month – by mean 1.5 at all sites. It reached mean 4.4 ± 0.7 (p < 0.01) at the great toe, 4.9 ± 0.7 (p < 0.01) at the 1st metatarsal and 5.0 ± 1.0 (p < 0.01) at the medial malleolus. EMG showed increase in nerve conduction velocity of some nerves in some of the patients.